Curated News
By: NewsRamp Editorial Staff
July 15, 2026

Tonix Pharma Reveals Mpox Clade IIb Is 100,000x Less Virulent

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Tonix's TNX-801 vaccine candidate gains edge with new data showing current U.S. mpox strain is far less virulent.
  • Tonix published preclinical research in Journal of Virology showing clade IIb mpox is 100,000 times less virulent than IIa.
  • New animal models help researchers understand emerging mpox variants, advancing vaccines to protect global health.
  • Mpox strain circulating in the U.S. is up to 100,000 times less virulent than historic clade IIa strain.

Impact - Why it Matters

This research matters because it provides critical insights into the virulence of the current mpox strain, enabling more targeted vaccine and treatment development. The new mouse models will help scientists evaluate emerging variants, potentially leading to better preparedness against future outbreaks and safeguarding public health.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced a groundbreaking study published in the peer-reviewed Journal of Virology that reveals stark differences in virulence between mpox virus clade IIb, the strain currently circulating in the U.S., and the historic clade IIa strain. Conducted at the company's research and development center, the study developed three new mouse models for investigating mpox pathogenesis and found that the clade IIb isolate is up to 100,000 times less virulent than clade IIa. These findings provide critical tools to evaluate vaccines and other medical countermeasures against mpox and smallpox.

Tonix believes these results support the continued development of TNX-801, its live attenuated horsepox virus vaccine candidate for preventing mpox and smallpox. The new animal models will enable researchers to better understand emerging mpox variants, assess vaccine durability and protective efficacy, and advance efforts to address the ongoing global threat. Tonix Pharmaceuticals is a fully-integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with a commercial portfolio that includes TONMYA™ for fibromyalgia, the first new treatment in over 15 years, as well as acute migraine products Zembrace® SymTouch® and Tosymra®. The company's pipeline also features TNX-2900 for Prader-Willi syndrome, monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for kidney transplant rejection prevention. For more details, visit the full press release at https://ibn.fm/ZlMkK.

This research underscores Tonix's commitment to addressing high unmet medical needs through innovative science. The findings are particularly timely given the ongoing global threat of mpox and the need for effective countermeasures. Tonix's development of TNX-801 and the new mouse models could significantly accelerate the evaluation of vaccines against emerging variants. Investors can stay updated with the latest news via the company's newsroom at https://ibn.fm/TNXP. BioMedWire, a specialized communications platform, continues to highlight such critical developments in the biotechnology and life sciences sectors.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharma Reveals Mpox Clade IIb Is 100,000x Less Virulent

blockchain registration record for this content.